Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA.
Division of Gastroenterology and Hepatology, Mayo Clinic Healthcare, London, UK.
Gastrointest Endosc. 2023 Apr;97(4):790-798.e2. doi: 10.1016/j.gie.2022.11.006. Epub 2022 Nov 17.
SCENIC (International Consensus Statement on Surveillance and Management of Dysplasia in IBD) guidelines recommend that visible dysplasia in patients with longstanding inflammatory bowel disease (IBD) should be endoscopically characterized using a modified Paris classification. This study aimed to determine the interobserver agreement (IOA) of the modified Paris classification and endoscopists' accuracy for pathology prediction of IBD visible lesions.
One hundred deidentified endoscopic still images and 30 videos of IBD visible colorectal lesions were graded by 10 senior and 4 trainee endoscopists from 5 tertiary care centers. Endoscopists were asked to assign 4 classifications for each image: the standard Paris classification, modified Paris classification, pathology prediction, and lesion border. Agreement was measured using Light's kappa coefficient. Consensus of ratings was assessed according to strict majority.
The overall Light's kappa for all study endpoints was between .32 and .49. In a subgroup analysis between junior and senior endoscopists, Light's kappa continued to be less than .6 with a slightly higher agreement among juniors. Lesions with the lowest agreement and no consensus were mostly classified as Is, IIa, and mixed Paris classification and sessile and superficial elevated for modified Paris classification. Endoscopist accuracy for prediction of dysplastic, nondysplastic, and serrated pathology was 77%, 56%, and 30%, respectively. There was a strong association (P < .001) between the given morphology classification and the predicted pathology with Ip lesions carrying a much lower expectation of dysplasia than Is/IIc/III and mixed lesions. The agreement for border prediction was .5 for junior and .3 for senior endoscopists.
This study demonstrates very low IOA for Paris and modified Paris classifications and low accuracy and IOA for lesion histopathology prediction. Revisions of these classifications are required to create a clinically useful risk stratification tool and enable eventual application of augmented intelligence tools.
SCENIC(炎症性肠病(IBD)异型增生监测和管理国际共识声明)指南建议,对患有长期炎症性肠病(IBD)的患者,应使用改良的巴黎分类法对可见异型增生进行内镜下特征描述。本研究旨在确定改良的巴黎分类法的观察者间一致性(IOA)以及内镜医师对 IBD 可见病变的病理预测的准确性。
10 名资深和 4 名来自 5 家三级护理中心的实习内镜医师对 100 张 IBD 可见结直肠病变的内镜静态图像和 30 段视频进行了评分。要求内镜医师为每张图像分配 4 种分类:标准巴黎分类、改良巴黎分类、病理预测和病变边界。使用 Light's kappa 系数衡量一致性。根据严格多数评估评分的一致性。
所有研究终点的总体 Light's kappa 值在.32 至.49 之间。在初级和高级内镜医师的亚组分析中,Light's kappa 仍然小于.6,初级内镜医师的一致性略高。一致性和共识最低的病变主要分为 Is、IIa 和混合巴黎分类以及改良巴黎分类的息肉状和浅表隆起。预测异型增生、非异型增生和锯齿状病理的内镜医师准确性分别为 77%、56%和 30%。给出的形态学分类与预测的病理之间存在很强的关联(P<.001),Ip 病变的异型增生可能性远低于 Is/IIc/III 和混合病变。边界预测的一致性为初级内镜医师.5,高级内镜医师.3。
本研究表明,巴黎和改良巴黎分类的观察者间一致性非常低,对病变组织病理学预测的准确性和观察者间一致性也较低。需要对这些分类进行修订,以创建一种临床有用的风险分层工具,并为最终应用增强型人工智能工具奠定基础。